CRON Cronos Group Inc.

4.670CAD+0.43%Mkt Cap: 1.25B $P/E: 17.96

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporiz…

HeadlineSourceTime
Older
Canadian Penny Stocks To Watch In September 2026

Global markets are adjusting to higher long term interest rates, with bond yields in countries like Australia moving toward levels not seen in years. That shift keeps investors focused on balance sheets and cash flow rather than hype. For Canadian penny stocks, it creates a window to look at lower priced businesses that still keep their finances in order. This article breaks down three such opportunities from our financially focused screener. The three penny stocks covered below are only a...

Simply Wall St.
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions

Cronos Group (NASDAQ:CRON) used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation. Chief Executive Officer Mike Goren

MarketBeat
3 Canadian Penny Stocks To Watch With Up To 95% Fair Value Discount

Higher energy costs and supply chain risks are putting pressure on global manufacturers, which makes financial resilience matter more than ever for smaller companies. For Canadian penny stocks, that creates a window where stronger balance sheets and cleaner cash profiles can stand out. This article walks through three financially solid, low-priced stocks from our screener that aim to combine speculative upside with tighter risk controls. The three tickers in this piece are only a small...

Simply Wall St.
2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve and Cronos are turning stronger results into market-beating gains.

Motley Fool
Cronos Group (CRON) Returns To Profit Amid A Renewed Trade Threat

On August 6, Cronos Group (NASDAQ:CRON) reported second quarter results that finally paired growth with profitability. Net revenue climbed 58% year over year to $53.0 million, but the number that stands out is the bottom line: net income of $35.7 million, compared with a $38.5 million loss a year earlier. The company also disclosed a […]

Insider Monkey
Are Medical Stocks Lagging Cronos Group (CRON) This Year?

Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Zacks
Cronos Stock And 2 Profitable Penny Stocks With Stronger Balance Sheets

Global bond markets are now pricing in higher policy rates as inflation stays in focus. That backdrop pushes investors toward parts of the market where every dollar is scrutinised, including penny stocks. Financially Fit Penny Stocks apply a strict lens to smaller companies under 5 a share, with an emphasis on balance sheet strength. This article highlights 3 stocks from the screener that aim to balance potential with resilience. The three stocks below are just a starting sample from this...

Simply Wall St.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

Market Exclusive
Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests – Quarterly Update Report

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB’s leadership across global medical markets. Adjusted gross margin reached 58%, […] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests

Exec Edge
Cronos Group Inc (CRON) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...

Despite regulatory hurdles, Cronos Group Inc (CRON) posts record net revenue and gross profit, driven by strong Canadian brand performance and international momentum.

GuruFocus.com
Why Cronos Group (TSX:CRON) Is Up 6.4% After Swinging To US$32 Million Quarterly Profit

Cronos Group Inc. has reported its second-quarter 2026 results, with sales rising to US$70.6 million and revenue to US$53.01 million, alongside a shift from a net loss to net income of US$32.09 million compared with the same period last year. This move into profitability, with basic earnings per share from continuing operations at US$0.09 versus a loss per share a year earlier, highlights a clear improvement in operating performance over both the quarter and first half of 2026. We’ll now...

Simply Wall St.
Cronos Group Q2 Earnings Call Highlights

Cronos Group (NASDAQ:CRON) reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany. Consolidated net revenue rose 58% year over year to $53 million, while gross profit increased 9

MarketBeat
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks